Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
New York, NY
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Charlotte, NC
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Greensboro, NC
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Tulsa, OK
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Rock Hill, SC
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Nashville, TN
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Salt Lake City, UT
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Falls Church, VA
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Seattle, WA
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated:  5/30/2017
Auburn University
mi
from
Auburn, AL
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated: 5/30/2017
Auburn University
mi
from
Auburn, AL
Click here to add this to my saved trials
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated:  5/30/2017
Keck Graduate Institute School of Pharmacy
mi
from
Claremont, CA
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated: 5/30/2017
Keck Graduate Institute School of Pharmacy
mi
from
Claremont, CA
Click here to add this to my saved trials
Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
Status: Enrolling
Updated:  5/30/2017
George Washington University Medical Center
mi
from
Washington, D.C.,
Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
Status: Enrolling
Updated: 5/30/2017
George Washington University Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Antiretroviral Drug Interaction Study in Volunteers With HIV
The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers
Status: Enrolling
Updated:  5/31/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Antiretroviral Drug Interaction Study in Volunteers With HIV
The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers
Status: Enrolling
Updated: 5/31/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Parasitic Infections of the Gastrointestinal Tract
Study of Patients With Parasitic Infections of the Gastrointestinal Tract
Status: Enrolling
Updated:  6/1/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Parasitic Infections of the Gastrointestinal Tract
Study of Patients With Parasitic Infections of the Gastrointestinal Tract
Status: Enrolling
Updated: 6/1/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
Status: Enrolling
Updated:  6/8/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
Status: Enrolling
Updated: 6/8/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Beverly Hills, CA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Fresno, CA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Laguna Beach, CA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Laguna Beach, CA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Long Beach, CA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Tarzana, CA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Tarzana, CA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Denver, CO
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Fort Collins, CO
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Hollywood, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Miami, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Plantation, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Plantation, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Tampa, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
West Palm Beach, FL
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Lexington, KY
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Louisville, KY
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
New Orleans, LA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Shreveport, LA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Detroit, MI
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Jackson, MS
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Hillsborough, NJ
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Somers Point, NJ
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Brooklyn, NY
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
New York, NY
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Rochester, NY
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Valhalla, NY
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Valhalla, NY
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Charlotte, NC
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Akron, OH
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Tulsa, OK
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Columbia, SC
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Columbia, SC
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Dallas, TX
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials